Inhibition of Wnt Signaling by Atovaquone Inhibits Gastric Cancer and Enhances Chemotherapy Effectiveness Through Activation of Casein Kinase 1α

References

• Sekiguchi M, Oda I, Matsuda T, Saito Y. Epidemiological trends and future perspectives of gastric cancer in Eastern Asia. Digestion. 2022;103(1):22–8. doi: 10.1159/000518483.
   PubMed Web of Science ®Google Scholar
• Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014;345(2):196–202. doi: 10.1016/j.canlet.2013.08.016.
   PubMed Web of Science ®Google Scholar
• Baj J, Korona-Głowniak I, Forma A, Maani A, Sitarz E, Rahnama-Hezavah M, Radzikowska E, Portincasa P. Mechanisms of the epithelial-mesenchymal transition and tumor microenvironment in helicobacter pylori-induced gastric cancer. Cells. 2020;9(4):1055. doi: 10.3390/cells9041055.
   PubMed Web of Science ®Google Scholar
• Patrad E, Khalighfard S, Amiriani T, Khori V, Alizadeh AM. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy. Cell Oncol . 2022;45(6):1073–117. doi: 10.1007/s13402-022-00715-3.
   Web of Science ®Google Scholar
• Chiurillo MA. Role of the Wnt/beta-catenin pathway in gastric cancer: an in-depth literature review. World J Exp Med. 2015;5(2):84–102. doi: 10.5493/wjem.v5.i2.84.
   PubMedGoogle Scholar
• Akhavanfar R, Shafagh S-G, Mohammadpour B, Farahmand Y, Lotfalizadeh MH, Kookli K, Adili A, Siri G, Eshagh Hosseini SM. A comprehensive insight into the correlation between ncRNAs and the Wnt/beta-catenin signalling pathway in gastric cancer pathogenesis. Cell Commun Signal. 2023;21(1):166. doi: 10.1186/s12964-023-01092-6.
   PubMed Web of Science ®Google Scholar
• Yoon JC, Ng A, Kim BH, Bianco A, Xavier RJ, Elledge SJ. Wnt signaling regulates mitochondrial physiology and insulin sensitivity. Genes Dev. 2010;24(14):1507–18. doi: 10.1101/gad.1924910.
   PubMed Web of Science ®Google Scholar
• Kim S, Jho EH. The protein stability of Axin, a negative regulator of Wnt signaling, is regulated by Smad ubiquitination regulatory factor 2 (Smurf2). J Biol Chem. 2010;285(47):36420–6. doi: 10.1074/jbc.M110.137471. M110.137471 [pii]
   PubMed Web of Science ®Google Scholar
• Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol. 1992;43(7):1545–53. 10.1016/0006-2952(92)90213-3
   PubMed Web of Science ®Google Scholar
• Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem. 1997;272(7):3961–6. 10.1074/jbc.272.7.3961
   PubMed Web of Science ®Google Scholar
• Lv Z, Yan X, Lu L, Su C, He Y. Atovaquone enhances doxorubicin’s efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer. J Bioenerg Biomembr. 2018;50(4):263–70. doi: 10.1007/s10863-018-9755-y.
   PubMed Web of Science ®Google Scholar
• Ke F, Yu J, Chen W, Si X, Li X, Yang F, Liao Y, Zuo Z. The anti-malarial atovaquone selectively increases chemosensitivity in retinoblastoma via mitochondrial dysfunction-dependent oxidative damage and Akt/AMPK/mTOR inhibition. Biochem Biophys Res Commun. 2018;504(2):374–9. doi: 10.1016/j.bbrc.2018.06.049.
   PubMed Web of Science ®Google Scholar
• Gao X, Liu X, Shan W, Liu Q, Wang C, et al. Anti-malarial atovaquone exhibits anti-tumor effects by inducing DNA damage in hepatocellular carcinoma. Am J Cancer Res. 2018;8:1697–711.
   PubMed Web of Science ®Google Scholar
• Chen D, Sun X, Zhang X, Cao J. Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy. J Biochem Mol Toxicol. 2018;32(9):e22195. doi: 10.1002/jbt.22195.
   PubMed Web of Science ®Google Scholar
• Tian S, Chen H, Tan W. Targeting mitochondrial respiration as a therapeutic strategy for cervical cancer. Biochem Biophys Res Commun. 2018;499(4):1019–24. doi: 10.1016/j.bbrc.2018.04.042.
   PubMed Web of Science ®Google Scholar
• Xiang M, Kim H, Ho VT, Walker SR, Bar-Natan M, Anahtar M, Liu S, Toniolo PA, Kroll Y, Jones N, et al. Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. 2016;128(14):1845–53. doi: 10.1182/blood-2015-07-660506.
   PubMed Web of Science ®Google Scholar
• Stevens AM, Xiang M, Heppler LN, Tošić I, Jiang K, Munoz JO, Gaikwad AS, Horton TM, Long X, Narayanan P, et al. Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv. 2019;3(24):4215–27. doi: 10.1182/bloodadvances.2019000499.
   PubMed Web of Science ®Google Scholar
• Takabe H, Warnken ZN, Zhang Y, Davis DA, Smyth HDC, Kuhn JG, Weitman S, Williams Iii RO. A repurposed drug for brain cancer: enhanced atovaquone amorphous solid dispersion by combining a spontaneously emulsifying component with a polymer carrier. Pharmaceutics. 2018;10(2):60. doi: 10.3390/pharmaceutics10020060.
   PubMed Web of Science ®Google Scholar
• Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, Kelly CJ, Pirovano G, Buffa FM, Hammond EM, et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nat Commun. 2016;7(1):12308. doi: 10.1038/ncomms12308.
   PubMedGoogle Scholar
• Gupta N, Srivastava SK. Atovaquone suppresses the growth of metastatic triple-negative breast tumors in lungs and brain by inhibiting integrin/FAK signaling axis. Pharmaceuticals. 2021;14(6):521. doi: 10.3390/ph14060521.
   Web of Science ®Google Scholar
• Gupta N, Srivastava SK. Atovaquone: an antiprotozoal drug suppresses primary and resistant breast tumor growth by inhibiting HER2/beta-catenin signaling. Mol Cancer Ther. 2019;18(10):1708–20. doi: 10.1158/1535-7163.MCT-18-1286.
   PubMed Web of Science ®Google Scholar
• Liao Y, Chen W, Shi W, Zha H. Targeting cPLA2alpha inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras/MEK/ERK and Akt/beta-catenin pathways. Cancer Chemother Pharmacol. 2021;88(4):689–97. doi: 10.1007/s00280-021-04322-1.
   PubMed Web of Science ®Google Scholar
• Hashiguchi K, Zhang-Akiyama QM. Establishment of human cell lines lacking mitochondrial DNA. Methods Mol Biol. 2009;554:383–91. doi: 10.1007/978-1-59745-521-3_23.
   PubMedGoogle Scholar
• Veeman MT, Slusarski DC, Kaykas A, Louie SH, Moon RT. Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr Biol. 2003;13(8):680–5. doi: S0960982203002409. [pii]
   PubMed Web of Science ®Google Scholar
• Falloon J, Sargent S, Piscitelli SC, Bechtel C, LaFon SW, Sadler B, Walker RE, Kovacs JA, Polis MA, Davey RT, et al. Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. Pharmacotherapy. 1999;19(9):1050–6. doi: 10.1592/phco.19.13.1050.31598.
   PubMed Web of Science ®Google Scholar
• Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer. 2012;15(3):252–64. doi: 10.1007/s10120-011-0102-9.
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Ikehara Y, Kodera Y, Ikehara S, Yatabe Y, Mochizuki Y, Koike M, Fujiwara M, Nakao A, Tatematsu M, et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer. 2006;95(11):1504–13. doi: 10.1038/sj.bjc.6603459.
   PubMed Web of Science ®Google Scholar
• Ji J, Chen X, Leung SY, Chi J-TA, Chu KM, Yuen ST, Li R, Chan ASY, Li J, Dunphy N, et al. Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. Oncogene. 2002;21(42):6549–56. doi: 10.1038/sj.onc.1205829.
   PubMed Web of Science ®Google Scholar
• Ke Y, Ning T, Wang B. Establishment and characterization of a SV40 transformed human fetal gastric epithelial cell line-GES-1. Zhonghua Zhong Liu Za Zhi. 1994;16(1):7–10.
   PubMedGoogle Scholar
• Gao C-F, Xie Q, Su Y-L, Koeman J, Khoo SK, Gustafson M, Knudsen BS, Hay R, Shinomiya N, Vande Woude GF, et al. Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A. 2005;102(30):10528–33. doi: 10.1073/pnas.05043671020504367102. [pii].
   PubMed Web of Science ®Google Scholar
• Guo Y, Hu B, Fu B, Zhu H. Atovaquone at clinically relevant concentration overcomes chemoresistance in ovarian cancer via inhibiting mitochondrial respiration. Pathol Res Pract. 2021;224:153529. doi: 10.1016/j.prp.2021.153529.
   PubMed Web of Science ®Google Scholar
• Fiorillo M, Lamb R, Tanowitz HB, Mutti L, Krstic-Demonacos M, Cappello AR, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget. 2016;7(23):34084–99. doi: 10.18632/oncotarget.9122.
   PubMedGoogle Scholar
• Xie F, Gong J, Tan H, Zhang H, Ma J. Preclinical evidence of synergism between atovaquone and chemotherapy by AMPK-dependent mitochondrial dysfunction. Eur J Pharmacol. 2021;907:174256. doi: 10.1016/j.ejphar.2021.174256.
   PubMed Web of Science ®Google Scholar
• Fu C, Xiao X, Xu H, Lu W, Wang Y. Efficacy of atovaquone on EpCAM(+)CD44(+) HCT-116 human colon cancer stem cells under hypoxia. Exp Ther Med. 2020;20(6):286–1. doi: 10.3892/etm.2020.9416.
   PubMed Web of Science ®Google Scholar
• Kapur A, Mehta P, Simmons AD, Ericksen SS, Mehta G, Palecek SP, Felder M, Stenerson Z, Nayak A, Dominguez JMA, et al. Atovaquone: an inhibitor of oxidative phosphorylation as studied in gynecologic cancers. Cancers . 2022;14(9):2297. doi: 10.3390/cancers14092297.
   PubMed Web of Science ®Google Scholar
• Zhao J. Cancer stem cells and chemoresistance: the smartest survives the raid. Pharmacol Ther. 2016;160:145–58. doi: 10.1016/j.pharmthera.2016.02.008.
   PubMed Web of Science ®Google Scholar
• Li X, Wang H, Li Z, Li D, Lu X, Ai S, Dong Y, Liu S, Wu J, Guan W, et al. Oxygen tank for synergistic hypoxia relief to enhance mitochondria-targeted photodynamic therapy. Biomater Res. 2022;26(1):47. doi: 10.1186/s40824-022-00296-0.
   PubMedGoogle Scholar
• Liu J, Bai X, Zhang M, Wu S, Xiao J, Zeng X, Li Y, Zhang Z. Energy metabolism: a new target for gastric cancer treatment. Clin Transl Oncol. 2023;26(2):338–51. doi: 10.1007/s12094-023-03278-3.
   PubMed Web of Science ®Google Scholar
• Lee SY, Jeon HM, Ju MK, Kim CH, Yoon G, Han SI, Park HG, Kang HS. Wnt/Snail signaling regulates cytochrome C oxidase and glucose metabolism. Cancer Res. 2012;72(14):3607–17. doi: 10.1158/0008-5472.CAN-12-0006.
   PubMed Web of Science ®Google Scholar
• Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, Jernigan KK, Meyers KC, Hang BI, Waterson AG, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol. 2010;6(11):829–36. doi: 10.1038/nchembio.453. nchembio.453 [pii]
   PubMed Web of Science ®Google Scholar
• Li J, Jiang Y, Wang P, Ke S, Yang L, Shen Y. Casein kinase 1alpha-dependent inhibition of Wnt/beta-catenin selectively targets nasopharyngeal carcinoma and increases chemosensitivity. Anticancer Drugs. 2019;30(7):e0747. doi: 10.1097/CAD.0000000000000747.
   PubMed Web of Science ®Google Scholar
• Song X, Xin N, Wang W, Zhao C. Wnt/beta-catenin, an oncogenic pathway targeted by H. pylori in gastric carcinogenesis. Oncotarget. 2015;6(34):35579–88. doi: 10.18632/oncotarget.5758.
   PubMedGoogle Scholar
• Li LF, Wei ZJ, Sun H, Jiang B. Abnormal beta-catenin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis. World J Gastroenterol. 2014;20(34):12313–21. doi: 10.3748/wjg.v20.i34.12313.
   PubMed Web of Science ®Google Scholar